$10.19
▼ -0.3% Today
as of Sep 4, 16:52 ET
Last 30 days
Recent Press Releases & News
Novavax to Participate in September Investor Conferences
Novavax Jumps 6% on Matrix-M Oncology Speculation: Is the Royalty Model the Real Story?
How Expanded Nuvaxovid Royalties and Partner-led Execution Could Shape Novavax’s (NVAX) Investment Narrative
Overview
52-week range
$6.20
$12
69% of range
Avg surprise (last 3)
+458.1%
Avg reaction (last 2)
+13.7%
100% positive
Latest IV / EM
56%
EM ±2.3% · $11 · Sep 4
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-0.32 | — | — | — | — | financials |
| Wed May 6, 2026 | Mar/2026 | $-0.06 | $-0.25 | +76.0% | -102.0% | +15.6% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-1.25 | — | — | — | — | financials |
| Wed Aug 6, 2025 | Jun/2025 | $0.62 | $-0.07 | +985.7% | — | — | earnings |
| Thu May 8, 2025 | Mar/2025 | $2.93 | $0.71 | +312.7% | — | +11.9% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.76 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $0.99 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-1.05 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-1.26 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $0.58 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-3.41 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $57M | $140M | — | $70M | $239M | $667M | — | $85M |
| Cost of revenue | $14M | $31M | — | $21M | $15M | $14M | — | $61M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-55M | $-15M | — | $-178M | $101M | $516M | — | $-134M |
| Net income | $-53M | $-9M | — | $-202M | $107M | $519M | — | $-121M |
| EPS (diluted) | $-0.32 | $-0.06 | — | $-1.25 | $0.62 | $2.93 | — | $-0.76 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $191M | $228M | $241M | $268M | $254M | $263M | $530M | $574M |
| Inventory | $10M | $11M | $12M | $14M | $10M | $10M | $9M | $9M |
| Total current assets | $771M | $851M | $978M | $975M | $920M | $868M | $1.13B | $1.10B |
| Total assets | $956M | $1.04B | $1.18B | $1.18B | $1.34B | $1.29B | $1.56B | $1.71B |
| Long-term debt | $291M | $291M | $244M | — | — | — | — | — |
| Total liabilities | $1.15B | $1.19B | $1.30B | $1.34B | $1.30B | $1.37B | $2.18B | $2.24B |
| Total equity | $-191M | $-145M | $-128M | $-157M | $38M | $-76M | $-624M | $-526M |